GO:0003220 left ventricular cardiac muscle tissue morphogenesis: Developmental Process, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003220 describes the biological process that generates and organizes the anatomical structures of the left ventricular cardiac muscle tissue.
• Left ventricular morphogenesis depends on spatially restricted progenitor populations, including Hey2 enhancer-active unipotent progenitors in the juxta-cardiac field of the early mouse embryo.
• Notch signaling is a central regulator of ventricular chamber development, and its disruption is linked to cardiomyopathy.
• Epicardial cells contribute to the cellular complexity of the developing ventricle, and single-cell genomics has begun to resolve human epicardial heterogeneity in heart development and disease.
• Disorders of left ventricular morphogenesis, such as left ventricular noncompaction, are clinically important and have a strong genetic component.
• Studying this process requires developmental, genetic, and single-cell approaches that can resolve progenitor specification, tissue organization, and disease-associated remodeling.
Description
Left ventricular cardiac muscle tissue morphogenesis (GO:0003220) is the biological process in which the anatomical structures of the left cardiac ventricle muscle are generated and organized. This process is fundamental to building a functional left ventricle, the chamber responsible for systemic circulation, and it depends on the coordinated specification, proliferation, and organization of cardiac progenitors. In the early mouse embryo, a population of unipotent progenitors marked by Hey2 enhancer activity in the juxta-cardiac field has been shown to contribute specifically to left ventricular cardiomyocytes. This finding illustrates that left ventricular morphogenesis is not a generic cardiac process but one with dedicated progenitor sources and regulatory logic. Beyond progenitor specification, ventricular chamber development requires signaling pathways that pattern the myocardium and coordinate growth with tissue architecture; Notch signaling has emerged as a key regulator of ventricular chamber development and is implicated in cardiomyopathy when perturbed. The cellular ecosystem of the developing ventricle also includes epicardial cells, whose heterogeneity and contributions to heart development and disease are now being resolved by single-cell genomics. Because defects in left ventricular morphogenesis underlie clinically significant conditions such as left ventricular noncompaction, understanding this GO term is directly relevant to developmental biology, genetics, and translational cardiology.
left ventricular cardiac muscle tissue morphogenesis At A Glance
| GO ID | GO:0003220 |
|---|---|
| GO term | left ventricular cardiac muscle tissue morphogenesis |
| Ontology | biological_process |
| Synonym | left ventricular myocardium morphogenesis |
| Definition | The process in which the anatomical structures of left cardiac ventricle muscle are generated and organized. |
| Major function | Generation and organization of left ventricular cardiac muscle tissue during development. |
| Key developmental context | Specification and contribution of left ventricular progenitors, including Hey2 enhancer-active unipotent progenitors in the juxta-cardiac field. |
| Major regulatory pathway | Notch signaling in ventricular chamber development and cardiomyopathy. |
| Associated cell population | Epicardial cells, whose heterogeneity is resolved by single-cell genomics in heart development and disease. |
| Disease relevance | Left ventricular noncompaction and related cardiomyopathies. |
What Is GO:0003220?
GO:0003220, left ventricular cardiac muscle tissue morphogenesis, is the process in which the anatomical structures of left cardiac ventricle muscle are generated and organized. In practical terms, it covers the developmental steps that build the muscular wall of the left ventricle, including the specification and expansion of left ventricular cardiomyocyte progenitors, the assembly of myocardial tissue architecture, and the organization of the muscle into a functional chamber. The synonym left ventricular myocardium morphogenesis reflects that the process is centered on the myocardium, the muscle tissue of the left ventricle. This is a biological_process term, meaning it describes a developmental program rather than a single molecular activity or a static cellular component.
Why Is left ventricular cardiac muscle tissue morphogenesis Important in Cell Biology?
Left ventricular cardiac muscle tissue morphogenesis is important because the left ventricle is the principal pumping chamber of the heart, and its developmental construction determines lifelong cardiac function. Disruption of the progenitor programs and signaling pathways that build the left ventricular myocardium can lead to structural heart disease, including left ventricular noncompaction, a condition characterized by excessive trabeculation and deep intertrabecular recesses that is associated with heart failure, arrhythmias, and thromboembolism. Genetic studies have reinforced the clinical importance of this process by identifying inherited contributions to left ventricular noncompaction and by supporting risk stratification based on genetic and clinical features. In addition, Notch signaling is required for normal ventricular chamber development, and its dysregulation has been linked to cardiomyopathy, underscoring that morphogenetic pathways are directly connected to disease. Because the cellular composition of the developing ventricle includes epicardial and other non-myocyte populations that influence myocardial organization, understanding GO:0003220 requires an integrated view of progenitor biology, signaling, and tissue architecture.
• Defines the developmental program that builds the muscular wall of the left ventricle, the heart's systemic pump.
• Provides a framework for studying left ventricular progenitor specification, including Hey2 enhancer-active unipotent progenitors.
• Connects ventricular chamber development to Notch signaling, a pathway repeatedly implicated in cardiomyopathy.
• Explains the cellular complexity of the developing ventricle, including epicardial contributions resolved by single-cell genomics.
• Underlies left ventricular noncompaction, a cardiomyopathy with excessive trabeculation and clinical complications.
• Supports genetic risk stratification in left ventricular noncompaction and related inherited cardiac conditions.
• Informs developmental models of congenital and acquired structural heart disease.
• Guides the design of CRISPR-based models to test candidate genes in left ventricular morphogenesis.
• Links developmental morphogenesis to adult cardiac remodeling and repair biology.
• Provides a conceptual bridge between single-cell developmental atlases and functional validation experiments.
What Happens During left ventricular cardiac muscle tissue morphogenesis?
Specification of left ventricular progenitors
In simple terms: Certain early embryonic cells are set aside to become the muscle of the left ventricle.
Left ventricular cardiac muscle tissue morphogenesis begins with the specification of progenitor cells that are committed to forming left ventricular cardiomyocytes. In the early mouse embryo, a population of unipotent progenitors marked by Hey2 enhancer activity in the juxta-cardiac field has been identified as a source of left ventricular cardiomyocytes. This indicates that the left ventricle is not built from an entirely uniform pool of cardiac progenitors but receives contributions from spatially and molecularly distinct progenitor populations. The existence of such dedicated progenitors provides a developmental basis for the regional identity of the left ventricular myocardium and helps explain why the left ventricle acquires chamber-specific properties.
Notch-dependent ventricular chamber development
In simple terms: A cell-to-cell signaling system called Notch helps shape the developing ventricular chambers.
Notch signaling is a central regulator of ventricular chamber development, and its activity is required for normal chamber morphogenesis. Perturbation of Notch signaling in the developing ventricle is associated with cardiomyopathy, indicating that this pathway couples morphogenetic decisions to long-term cardiac function. The involvement of Notch in ventricular chamber development places it among the key regulatory inputs that act during left ventricular cardiac muscle tissue morphogenesis, alongside progenitor specification programs such as those marked by Hey2 enhancer activity. Together, these findings support a model in which signaling pathways and progenitor identity are integrated to build the ventricular chamber.
Epicardial contributions to ventricular tissue organization
In simple terms: The outer layer of the heart provides cells and signals that help organize the developing ventricle.
The developing ventricle is a multicellular tissue in which epicardial cells contribute to heart development and disease. Single-cell genomics of human epicardium has uncovered principles of epicardial biology in heart development and disease, revealing heterogeneity among epicardial cells and their derivatives. These epicardial populations can influence myocardial organization and provide paracrine signals that shape the ventricular wall. Because left ventricular cardiac muscle tissue morphogenesis requires the coordinated assembly of myocardium with surrounding cell types, epicardial biology is an integral part of the process rather than a separate phenomenon.
Myocardial tissue assembly and chamber organization
In simple terms: The muscle cells organize into a structured wall that forms the left ventricle.
Once left ventricular progenitors are specified and the chamber-level signaling environment is established, cardiomyocytes must assemble into organized myocardial tissue. This step involves the arrangement of cardiomyocytes into a coherent muscular wall and the establishment of the anatomical structures of the left cardiac ventricle muscle, as defined by GO:0003220. The process is influenced by the progenitor origins of the cells, including Hey2 enhancer-active progenitors that contribute specifically to left ventricular cardiomyocytes, and by signaling pathways such as Notch that pattern the ventricular chamber. The resulting tissue architecture is essential for the mechanical function of the left ventricle and for its capacity to withstand hemodynamic load after birth.
Integration with cardiac injury and remodeling programs
In simple terms: The same cell types and signals that build the left ventricle also respond when the heart is injured.
Although GO:0003220 is a developmental process, its cellular and signaling components overlap with those activated after cardiac injury. After acute myocardial infarction, angiogenesis is induced in the heart and contributes to repair and remodeling. Cardiac macrophages, including tissue-resident CCR2- and CCR2+ populations, differentially orchestrate monocyte recruitment and fate specification following myocardial injury. These injury responses do not recapitulate left ventricular morphogenesis, but they engage overlapping cell types and signaling principles, making developmental knowledge of GO:0003220 relevant to understanding adult cardiac remodeling.
Key Genes Involved in GO:0003220 left ventricular cardiac muscle tissue morphogenesis
The following genes and proteins have been implicated in left ventricular cardiac muscle tissue morphogenesis or in closely related ventricular development and disease processes, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HEY2 | Marks unipotent progenitors for left ventricular cardiomyocytes in the juxta-cardiac field of early mouse embryo | Defines a progenitor population dedicated to left ventricular cardiomyocyte formation |
| NOTCH1 | Component of Notch signaling, a central regulator of ventricular chamber development and cardiomyopathy | Provides a signaling entry point for studying ventricular chamber morphogenesis |
| NOTCH2 | Component of Notch signaling in ventricular chamber development | Candidate for pathway-level perturbation studies in ventricular morphogenesis |
| JAG1 | Notch ligand implicated in ventricular chamber development and cardiomyopathy | Ligand-side manipulation of Notch signaling in ventricular development |
| DLL4 | Notch ligand associated with ventricular chamber development and cardiomyopathy | Ligand-side manipulation of Notch signaling in ventricular development |
| RBPJ | Canonical Notch transcriptional effector in ventricular chamber development | Core pathway node for loss-of-function studies in ventricular morphogenesis |
| MYH7 | Sarcomeric myosin heavy chain expressed in ventricular myocardium; relevant to left ventricular noncompaction genetics | Candidate gene for cardiomyopathy-associated morphogenetic defects |
| MYBPC3 | Sarcomeric protein implicated in inherited cardiomyopathies relevant to left ventricular noncompaction | Candidate gene for functional validation in ventricular disease models |
| TTN | Large sarcomeric protein frequently implicated in inherited cardiomyopathies relevant to left ventricular noncompaction | Candidate gene for variant modeling in ventricular disease |
| ACTC1 | Sarcomeric actin implicated in inherited cardiac conditions relevant to left ventricular noncompaction | Candidate gene for sarcomere-focused morphogenesis studies |
| TNNT2 | Sarcomeric troponin implicated in inherited cardiomyopathies relevant to left ventricular noncompaction | Candidate gene for contractile apparatus studies in ventricular disease |
| TPM1 | Sarcomeric tropomyosin implicated in inherited cardiac conditions relevant to left ventricular noncompaction | Candidate gene for sarcomere-focused morphogenesis studies |
| MYL2 | Sarcomeric myosin light chain implicated in inherited cardiomyopathies relevant to left ventricular noncompaction | Candidate gene for functional validation in ventricular disease models |
| MYL3 | Sarcomeric myosin light chain implicated in inherited cardiomyopathies relevant to left ventricular noncompaction | Candidate gene for functional validation in ventricular disease models |
| CCR2 | Marks cardiac macrophage subsets that orchestrate monocyte recruitment and fate specification after myocardial injury | Provides a tool for studying injury-associated remodeling that overlaps with developmental cell populations |
| VEGFA | Central regulator of angiogenesis after acute myocardial infarction | Relevant to injury-associated vascular responses in the heart |
| KDR | VEGF receptor mediating angiogenic signaling after myocardial infarction | Candidate for studying vascular contributions to cardiac repair |
| PECAM1 | Endothelial marker used to study angiogenesis after acute myocardial infarction | Endpoint marker for vascular organization in cardiac tissue |
How Is left ventricular cardiac muscle tissue morphogenesis Regulated?
Left ventricular cardiac muscle tissue morphogenesis is regulated by at least two broad layers of control: progenitor-intrinsic programs and intercellular signaling. The Hey2 enhancer defines a progenitor population with unipotent potential for left ventricular cardiomyocytes in the juxta-cardiac field, indicating that transcriptional enhancer activity is a regulatory mechanism that restricts progenitor fate. Notch signaling provides a second layer of regulation, acting during ventricular chamber development and being required for normal morphogenesis; its perturbation is associated with cardiomyopathy. Epicardial cells add a third layer by contributing paracrine and cellular inputs that shape the developing ventricle, as revealed by single-cell genomic studies of human epicardium in heart development and disease. Together, these mechanisms ensure that left ventricular myocardial tissue is generated with the correct size, shape, and cellular composition.
left ventricular cardiac muscle tissue morphogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HEY2 | Left ventricular progenitor specification and ventricular morphogenesis | Knockout or lineage-tracing knock-in in mouse embryonic stem cells and embryos |
| NOTCH1 | Ventricular chamber development and cardiomyopathy | Point mutation or knockout in cardiomyocyte differentiation models |
| MYH7 | Left ventricular noncompaction and inherited cardiomyopathy | Knock-in of patient-associated variants in iPSC-derived cardiomyocytes |
| MYBPC3 | Left ventricular noncompaction and inherited cardiomyopathy | Knockout or knock-in in iPSC-derived cardiomyocytes |
| TTN | Left ventricular noncompaction and inherited cardiomyopathy | Truncating variant knock-in in iPSC-derived cardiomyocytes |
Left ventricular noncompaction
Left ventricular noncompaction is a cardiomyopathy characterized by excessive trabeculation of the left ventricular myocardium and deep intertrabecular recesses, and it is clinically associated with heart failure, arrhythmias, and thromboembolism. The condition is widely regarded as a disorder of left ventricular morphogenesis, making GO:0003220 directly relevant to its pathogenesis. Genetic considerations are important in left ventricular noncompaction, and risk stratification incorporates genetic and clinical features. Because the morphogenetic program described by GO:0003220 builds the left ventricular myocardial wall, perturbations in this process provide a mechanistic framework for understanding noncompaction.
Notch-associated cardiomyopathy
Notch signaling is a central regulator of ventricular chamber development, and its dysregulation has been linked to cardiomyopathy. This connection places Notch pathway genes among the candidate modifiers of left ventricular cardiac muscle tissue morphogenesis and suggests that pathway-level perturbations during development can have lasting consequences for ventricular function. Studying Notch signaling in the context of GO:0003220 therefore provides a bridge between developmental morphogenesis and inherited or acquired cardiac disease.
Cardiac injury and remodeling
Although left ventricular cardiac muscle tissue morphogenesis is a developmental process, the cell types and signals involved overlap with those activated after cardiac injury. Angiogenesis is induced after acute myocardial infarction and contributes to repair and remodeling. Cardiac macrophages, including tissue-resident CCR2- and CCR2+ subsets, differentially orchestrate monocyte recruitment and fate specification following myocardial injury. These injury responses highlight that the cellular players relevant to ventricular tissue organization remain active in the adult heart and can influence disease outcomes.
From left ventricular cardiac muscle tissue morphogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene control left ventricular progenitor specification? | Knockout of the candidate gene in mouse embryonic stem cells or embryos with Hey2 enhancer-based progenitor readouts |
| Does a Notch pathway variant alter ventricular chamber morphogenesis? | Point mutation knock-in in cardiomyocyte differentiation cultures or mouse embryos |
| Does a sarcomeric variant cause noncompaction-like phenotypes? | Knock-in of patient-associated variants in iPSC-derived cardiomyocytes |
| Where is a candidate protein expressed during left ventricular development? | Tagged knock-in with fluorescent or epitope tags in embryonic models |
| Does overexpression of a signaling factor expand left ventricular myocardium? | Overexpression of the factor in cardiac progenitor or cardiomyocyte differentiation systems |
| Which cell populations contribute to left ventricular tissue organization? | Single-cell genomics of epicardial and myocardial populations combined with genetic perturbation |
How to Study the left ventricular cardiac muscle tissue morphogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-cell RNA sequencing | Cell-type and cell-state heterogeneity in developing heart tissue | Resolving epicardial and myocardial populations in ventricular development |
| Enhancer-based lineage tracing | Progenitor contribution to left ventricular cardiomyocytes | Defining unipotent progenitors in the juxta-cardiac field |
| Notch pathway perturbation | Effects of signaling gain or loss on ventricular chamber development | Testing Notch-dependent morphogenesis and cardiomyopathy mechanisms |
| Genetic variant functional assays | Impact of patient-associated variants on cardiomyocyte and tissue phenotypes | Modeling left ventricular noncompaction-associated variants |
| Histology and morphometry | Anatomical structure of the left ventricular myocardium | Assessing trabeculation and chamber architecture in disease models |
| Angiogenesis assays | Vascular responses in cardiac tissue | Studying injury-associated remodeling that overlaps with developmental programs |
| Macrophage fate mapping | Recruitment and fate specification of cardiac macrophage subsets | Investigating injury-associated cell populations in the heart |
| Clinical genetic testing | Inherited variants associated with left ventricular noncompaction | Risk stratification and family screening |
Single-cell genomics
Single-cell genomics has been used to uncover principles of human epicardium biology in heart development and disease, revealing heterogeneity among epicardial cells and their derivatives. Applied to left ventricular cardiac muscle tissue morphogenesis, single-cell approaches can resolve progenitor populations, including those marked by Hey2 enhancer activity, and can identify cell states that contribute to myocardial tissue assembly. These methods are particularly valuable for linking developmental cell populations to disease-relevant states.
Genetic lineage tracing and enhancer analysis
Enhancer-based lineage tracing has been used to define unipotent progenitors for left ventricular cardiomyocytes in the juxta-cardiac field of the early mouse embryo. This approach allows researchers to determine which progenitor populations contribute to the left ventricular myocardium and to test whether candidate regulatory elements are sufficient to mark specific lineages. Such experiments are essential for assigning causality to developmental observations.
Signaling pathway perturbation
Because Notch signaling is a central regulator of ventricular chamber development and cardiomyopathy, pathway perturbation experiments are a key method for studying GO:0003220. Gain- and loss-of-function manipulations of Notch components can reveal how signaling inputs shape ventricular chamber morphogenesis and how their disruption leads to disease phenotypes. These experiments are often combined with developmental staging and morphological analysis.
Disease modeling and variant functional assays
Left ventricular noncompaction has a strong genetic component, and risk stratification incorporates genetic considerations. Functional assays using patient-associated variants in sarcomeric and other candidate genes can test whether specific alleles disrupt left ventricular morphogenesis. These assays are typically performed in cardiomyocyte differentiation systems or animal models and are interpreted alongside clinical and genetic data.
How CRISPR Can Be Used to Study GO:0003220 left ventricular cardiac muscle tissue morphogenesis
Knockout
CRISPR knockout is used to test whether a candidate gene is required for left ventricular cardiac muscle tissue morphogenesis. For example, knocking out genes that mark or regulate left ventricular progenitors, such as Hey2 enhancer-associated factors, can reveal whether progenitor specification or expansion depends on the gene. Knockout of Notch pathway components can similarly test pathway requirement in ventricular chamber development. These experiments are typically performed in embryonic stem cell-derived cardiomyocyte systems or animal models, with readouts for progenitor markers and myocardial architecture.
Point Mutation
CRISPR point mutation is used to model specific patient-associated variants in genes linked to left ventricular morphogenesis and disease. Because left ventricular noncompaction has a strong genetic component, introducing precise variants into sarcomeric or other candidate genes allows researchers to test whether a given allele alters cardiomyocyte or tissue-level phenotypes. Point mutation models are particularly useful for distinguishing pathogenic from benign variants and for studying gene dosage effects.
Knock-in
CRISPR knock-in can be used to place reporters, tags, or humanized sequences at endogenous loci relevant to left ventricular morphogenesis. Tagged knock-in of progenitor markers allows visualization of left ventricular progenitor populations, such as those defined by Hey2 enhancer activity. Knock-in of disease-associated variants provides a controlled system for studying how specific alleles affect ventricular tissue organization. These models are valuable when endogenous regulation must be preserved.
Overexpression
CRISPR overexpression, for example via targeted integration of a strong promoter, can test whether increased dosage of a signaling factor or transcription factor expands or disrupts left ventricular myocardium. Overexpression of Notch pathway components can reveal gain-of-function effects on ventricular chamber development, while overexpression of angiogenic factors can probe vascular contributions to cardiac tissue. These experiments complement loss-of-function studies by defining sufficiency relationships.
How EDITGENE Supports left ventricular cardiac muscle tissue morphogenesis Research
Researchers studying left ventricular cardiac muscle tissue morphogenesis-related genes often need to determine whether a candidate gene is causally involved in progenitor specification, myocardial assembly, or disease-associated remodeling. Establishing causality requires controlled genetic perturbation, ideally with models that preserve endogenous regulation and allow precise allele-level manipulation. EDITGENE provides a suite of CRISPR-based services designed to support such studies, from knockout and point mutation to knock-in, overexpression, library screening, and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for left ventricular cardiac muscle tissue morphogenesis research.
Frequently Asked Questions About left ventricular cardiac muscle tissue morphogenesis
What is GO:0003220 left ventricular cardiac muscle tissue morphogenesis?
GO:0003220 is a biological_process term describing the process in which the anatomical structures of left cardiac ventricle muscle are generated and organized. It covers the developmental steps that build the muscular wall of the left ventricle, including progenitor specification and myocardial tissue assembly.
What genes are involved in left ventricular cardiac muscle tissue morphogenesis?
Genes implicated in this process include HEY2, which marks unipotent progenitors for left ventricular cardiomyocytes in the juxta-cardiac field, and Notch pathway components such as NOTCH1, NOTCH2, JAG1, DLL4, and RBPJ, which regulate ventricular chamber development. Sarcomeric genes such as MYH7, MYBPC3, TTN, ACTC1, TNNT2, TPM1, MYL2, and MYL3 are relevant to left ventricular noncompaction genetics.
How is Notch signaling related to left ventricular morphogenesis?
Notch signaling is a central regulator of ventricular chamber development, and its dysregulation is associated with cardiomyopathy. This places Notch pathway genes among the key regulatory inputs for left ventricular cardiac muscle tissue morphogenesis.
What is left ventricular noncompaction and how does it relate to GO:0003220?
Left ventricular noncompaction is a cardiomyopathy characterized by excessive trabeculation and deep intertrabecular recesses, and it is considered a disorder of left ventricular morphogenesis. Genetic factors contribute to its risk, and risk stratification incorporates genetic considerations.
Which progenitor cells form the left ventricular myocardium?
In the early mouse embryo, Hey2 enhancer activity defines unipotent progenitors for left ventricular cardiomyocytes in the juxta-cardiac field. These progenitors provide a dedicated source of left ventricular cardiomyocytes during development.
How can CRISPR be used to study left ventricular cardiac muscle tissue morphogenesis?
CRISPR knockout can test gene requirement, point mutation can model patient-associated variants, knock-in can tag or humanize loci, and overexpression can test gain-of-function effects. These approaches allow causal testing of candidate genes identified from developmental and genetic studies.
What methods are used to study left ventricular morphogenesis?
Methods include single-cell genomics to resolve epicardial and myocardial populations, enhancer-based lineage tracing to define progenitors, Notch pathway perturbation, and functional assays for disease-associated variants.
What is the role of epicardial cells in ventricular development?
Single-cell genomics of human epicardium has uncovered principles of epicardial biology in heart development and disease, revealing heterogeneity among epicardial cells that contribute to ventricular tissue organization.
Why is left ventricular morphogenesis important for heart disease?
Because the left ventricle is the main systemic pump, defects in its morphogenesis can lead to structural heart disease such as left ventricular noncompaction, which is associated with heart failure, arrhythmias, and thromboembolism.
What cell models are available for studying left ventricular morphogenesis genes?
Available models include CRISPR knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics services offered by EDITGENE.
Conclusion
GO:0003220 left ventricular cardiac muscle tissue morphogenesis is a defined developmental process that builds and organizes the muscular wall of the left ventricle. Research in mouse embryos has identified dedicated left ventricular progenitors marked by Hey2 enhancer activity, while Notch signaling has emerged as a central regulator of ventricular chamber development and a pathway linked to cardiomyopathy. Single-cell genomics of human epicardium has further revealed the cellular complexity of the developing ventricle. Clinically, disorders of left ventricular morphogenesis such as left ventricular noncompaction have a strong genetic component and significant morbidity. Together, these findings make GO:0003220 a valuable framework for integrating developmental biology, genetics, and disease modeling, and for designing CRISPR-based experiments that test causality in left ventricular myocardial development.
References
- 1. Wu X et al.. 2021. Angiogenesis after acute myocardial infarction.. Cardiovasc Res 117(5):1257-1273 PMID: 33063086
- 2. Bajpai G et al.. 2019. Tissue Resident CCR2- and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury.. Circ Res 124(2):263-278 PMID: 30582448
- 3. Meier AB et al.. 2023. Epicardioid single-cell genomics uncovers principles of human epicardium biology in heart development and disease.. Nat Biotechnol 41(12):1787-1800 PMID: 37012447
- 5. Watanabe Y et al.. 2023. Hey2 enhancer activity defines unipotent progenitors for left ventricular cardiomyocytes in juxta-cardiac field of early mouse embryo.. Proc Natl Acad Sci U S A 120(37):e2307658120 PMID: 37669370
- 6. Engberding R et al.. 2010. Isolated non-compaction cardiomyopathy.. Dtsch Arztebl Int 107(12):206-13 PMID: 20386670
- 7. D'Amato G et al.. 2016. Notch signalling in ventricular chamber development and cardiomyopathy.. FEBS J 283(23):4223-4237 PMID: 27260948
- 8. Ichida F. 2020. Left ventricular noncompaction - Risk stratification and genetic consideration.. J Cardiol 75(1):1-9 PMID: 31629663
